Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Enliven Therapeutics (ELVN) Assets Average (2020 - 2026)

Enliven Therapeutics has reported Assets Average over the past 7 years, most recently at $470.5 million for Q1 2026.

  • Quarterly results put Assets Average at $470.5 million for Q1 2026, up 49.77% from a year ago — trailing twelve months through Mar 2026 was $470.5 million (up 49.77% YoY), and the annual figure for FY2025 was $401.0 million, up 34.19%.
  • Assets Average reached $470.5 million in Q1 2026 per ELVN's latest filing, down from $483.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $497.4 million in Q3 2025 and bottomed at $61.9 million in Q3 2022.
  • Median Assets Average over the past 5 years was $307.3 million (2024), compared with a mean of $281.2 million.
  • The largest annual shift saw Assets Average plummeted 31.05% in 2022 before it skyrocketed 354.51% in 2023.
  • Over 5 years, Assets Average stood at $71.2 million in 2022, then skyrocketed by 283.36% to $273.0 million in 2023, then grew by 15.62% to $315.6 million in 2024, then soared by 53.21% to $483.5 million in 2025, then decreased by 2.69% to $470.5 million in 2026.
  • Business Quant data shows Assets Average for ELVN at $470.5 million in Q1 2026, $483.5 million in Q4 2025, and $497.4 million in Q3 2025.